Our client was a French biotech developing its first drug for neurological rare disease. The drug was granted an orphan drug designation a year before we met.Their international headquarters are in France. When they first came to Rare Insight, their pivotal Phase III study was ongoing. They wanted to open a subsidiary in Italy to start prelaunch activities.
First of all, Rare Insight conducted an early access program assessment with a specific focus on the disease at stake. We presented our local early access system. We made an assessment and scheduled a timeline for a potential early access program (or compassionate use) in our client’s orphan indication.Following this first step, Rare Insight proposed more cost-effective way to meet customers’ needs. Considering the size of the market and the future indication of their product, opening affiliates would have been very costly. Few days per month to start the activities was the appropriate level of resources needed for prelaunch activities.
Since 2017, Rare Insight has been working with this client on:
To coordinate these activities, Rare Insight appointed a Project Director who interacted with the costumers in systematic interactions (monthly reporting and teleconferences).